ePrivacy and GPDR Cookie Consent by TermsFeed Generator

Detail of the clinical trial

Title of the trial A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients with Relapsed or Refractory Hodgkin Lymphoma
EudraCT number 2018-002556-32
Protocol number ADCT-301-201
Sponsor ADC Therapeutics SA, Route de la Corniche 3B, 1066 Epalinges, Switzerland
Indications Oncology
Diagnosis Hodgkin Lymphoma
Population in clinical trial Adolescents (12-17 years)
Adults (18-65 years)
Elderly ( > 65 years)
Year of receiving the request to Institute (SÚKL) 2019
Date of approval by Institute (SÚKL) 23.1.2020
Date of approval by EC 2.10.2019
Date of initiation CT in ČR
Date of ending CT in ČR
Sites Všeobecná fakultní nemocnice v Praze ,Klinika hematologie VFN a 1. LF UK ,U Nemocnice 2,Praha 2,128 08 (discontinued)
Fakultní nemocnice Královské Vinohrady,Interní hematologická klinika,Šrobárova 1150/50,Praha 10,100 34 (discontinued)
Fakultní nemocnice Brno,Interní hematologická a onkologická klinika,Jihlavská 20,Brno,625 00

‹‹ Back to list